Neurohormonal activation and inflammation in chronic cardiopulmonary disease: A brief systematic review

Wiener Klinische Wochenschrift

Volumn 121, Issue 9-10, 2009, Pages 293-296

  Doehner, Wolfram ^a   Von Haehling, Stephan ^a   Anker, Stefan D ^a,b   Lainscak, Mitja ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

Cachexia; Cancer; Chronic heart failure; Chronic obstructive pulmonary disease; Inflammation; Neurohormones; Renin angiotensin aldosterone; Stroke; Sympatethic system

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUTICASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROHORMONE; NEUROHUMORAL ANTAGONIST; PLACEBO; SALMETEROL; UNCLASSIFIED DRUG;

CACHEXIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; HEALTH HAZARD; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; INFLAMMATION; INJURY; NEOPLASM; PHYLOGENY; PROGNOSIS; REVIEW; STROKE;

CACHEXIA; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HEART FAILURE; HUMANS; INFLAMMATION; NEUROTRANSMITTER AGENTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; STROKE;

EID: 69549108413     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-009-1194-7     Document Type: Review

References (42)

1. S von Haehling M Lainscak J Springer SD Anker 2009 Cardiac Cachexia: a systematic overview Pharmacol Ther 121 227 252
2. S Andreas SD Anker PD Scanlon VK Somers 2005 Neurohumoral activation as a link to systemic manifestations of chronic lung disease Chest 128 3618 3624
3. K Swedberg P Eneroth J Kjekshus S Snapinn 1990 Effects of enalapril and neuroendokrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group Am J Cardiol 66 40D 44D
4. S Strassburg SD Anker 2006 Metabolic and immunologic derangements in cardiac cachexia: where to from here? Heart Fail Rev 11 57 64
5. GS Filippatos SD Anker DT Kremastinos 2005 Pathophysiology of peripheral muscle wasting in cardiac cachexia Curr Opin Clin Nutr Metab Care 8 249 254
6. NM Hawkins MC Petrie PS Jhund GW Chalmers FG Dunn JJV McMurray 2009 Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology Eur J Heart Fail 11 130 139
7. AD Lopez CD Mathers M Ezzati DT Jamison CJ Murray 2006 Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data Lancet 367 1747 1757
8. N Firlei B Lamprecht L Schirnhofer B Kaiser M Studnicka 2007 The prevalence of COPD in Austria - the expected change over the next decade Wien Klin Wochenschr 119 513 518
9. M Lainscak L Majc Hodoscek HD Düngen M Rauchhaus W Doehner SD Anker, et al. 2009 The burden of chronic obstructive pulmonary disease in patients hospitalized for heart failure Wien Klin Wochenschrift 121 309 313
10. L Staszewsky M Wong S Masson S Barlera E Carretta AP Maggioni, et al. 2007 Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial J Card Fail 13 797 804
11. RG Narins ER Jones MC Stom MR Rudnick CP Bastl 1982 Diagnostic strategies in disorders of fluid, electrolyte and acid-base homeostasis Am J Med 72 496 520
12. IS Anand LD Fisher YT Chiang R Latini S Masson AP Maggioni, et al. 2003 Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) Circulation 107 1278 1283
13. K Dickstein A Cohen-Solal G Filippatos JJ McMurray P Ponikowski PA Poole-Wilson, et al. 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 Eur J Heart Fail 10 933 989
14. G Grassi G Seravalle DA Calhoun M Matturri G Mancia A Zanchetti 1992 Monitoring of sympathetic activity in man: physiology and pharmacology Eur Heart J 13 Suppl A 22 25
15. AM Watson SG Hood CN May 2006 Mechanisms of sympathetic activation in heart failure Clin Exp Pharmacol Physiol 33 1269 1274
16. F Waagstein A Hjalmarson E Varnauskas I Wallentin 1975 Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy Br Heart J 37 1022 1036
17. RH Straub HO Besedovsky A Del Rey 2007 Why are there analogous disease mechanisms in chronic inflammatory diseases? Wien Klin Wochenschr 119 444 454
18. M Lainscak S von Haehling SD Anker 2009 Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers Int J Cardiol 132 303 311
19. YD Tang SD Katz 2006 Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options Circulation 113 2454 2461
20. M Lainscak S von Haehling I Sarc K Ziherl W Doehner S Suskovic, et al. 2008 Anemia predicts survival in patients with chronic obstructive pulmonary disease Eur Respir J 32 Suppl 43s
21. M Rauchhaus W Doehner DP Francis C Davos M Kemp C Liebenthal, et al. 2000 Plasma cytokine parameters and mortality in patients with chronic heart failure Circulation 102 3060 3070
22. LM Fabbri F Luppi B Beghe KF Rabe 2008 Complex chronic comorbidities of COPD Eur Respir J 31 204 212
23. KF Rabe S Hurd A Anzueto PJ Barnes SA Buist P Calverley for the Global Initiative for Chronic Obstructive Lung Disease, et al. 2007 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 176 532 555
24. DD Sin SFP Man 2006 Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease Proc Am Thorac Soc 3 624 629
25. TA Lee AS Pickard DH Au B Bartle KB Weiss 2008 Risk for death associated with medicatins for recently diagnosed chronic obstructive pulmonary disease Ann Intern Med 149 380 390
26. PMA Calverly JA Anderson B Celli GT Ferguson C Jenkins PW Jones, et al. 2007 Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 775 789
27. WM Chatila BM Thomashow OA Minai GJ Criner BJ Make 2008 Comorbidities in chronic obstructive pulmonary disease Proc AM Thorac Soc 5 549 555
28. DD Sin NR Anthonisen JB Soriano AG Agusti 2006 Mortality in COPD: role of comorbidities Eur Respir J 28 1245 1257
29. GBJ Mancini M Etminan B Zhang LE Levesque JM FitzGerald JM Brophy 2006 Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease J Am Coll Cardiol 47 2554 2560
30. M Lainscak JG Cleland MJ Lenzen F Follath M Komajda K Swedberg 2007 International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey Eur J Heart Fail 9 292 299
31. M Lainscak C Moullet N Schön M Tendera 2007 Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience Int J Cardiol 122 149 155
32. SS Gottlieb RJ McCarter RA Vogel 1998 Effects of beta-blockade on mortality among high-risk and low-risk patietns after myocardial infarction N Engl J Med 339 489 497
33. YRBM Van Gestel SE Hoeks DD Sin GMJM Welten O Schouten HJ Witteveen, et al. 2008 Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis Am J Respir Crit Care Med 178 695 700
34. MT Dransfield SM Rowe JE Johnson WC Bailey LB Gerald 2008 Use of β blockers and the risk of death in hospitalized patients with acute exacerbations of COPD Thorax 63 301 305
35. S von Haehling SD Anker 2005 Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart 91 1 2
36. JI Keddissi WG Younis EA Chbeir NN Daher TA Dernaika GT Kinasewitz 2007 The use of statins and lung function in current and former smokers Chest 132 1764 1771
37. M Rauchhaus AJS Coats SD Anker 2000 The endotoxin-lipoprotein hypothesis Lancet 356 930 933
38. S Andreas C Herrmann-Lingen T Raupach L Lüthje JA Fabricius N Hruska, et al. 2006 Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Eur Respir J 27 972 979 (Pubitemid 44911111)
39. M Lainscak S Andreas PD Scanlon VK Somers SD Anker 2006 Ghrelin and neurohormonal antagonists in the treatment of cachexia associated with cardiopulmonary disease Int Med 45 837
40. HD Düngen S Apostolović S Inkrot E Tahirovic F Krackhardt M Pavlovic CIBIS-ELD Investigators, Subproject Multicenter Trials in the Competence Network Heart Failure, et al. 2008 Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial Clin Res Cardiol 97 578 586
41. J Schuler C Dückelmann W Beindl E Prinz T Michalski M Pichler 2008 Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria Wien Klin Wochenschr 120 733 741
42. M Schünemann SD Anker M Rauchhaus 2008 Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards onco-cardiology Nat Clin Pract Oncol 5 632 633